Immunity and vaccine development efforts against Trypanosoma cruzi

Lizette E. Rios, Juan Carlos Vázquez-Chagoyán, Antonio Ortega Pacheco, M. Paola Zago, Nisha J. Garg

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a critical lack of methods for prevention of infection or treatment of acute infection and chronic disease. Studies in experimental models have suggested that the protective immunity against T. cruzi infection requires the elicitation of Th1 cytokines, lytic antibodies and the concerted activities of macrophages, T helper cells, and cytotoxic T lymphocytes (CTLs). In this review, we summarize the research efforts in vaccine development to date and the challenges faced in achieving an efficient prophylactic or therapeutic vaccine against human CD.

Original languageEnglish (US)
Article number105168
JournalActa Tropica
StatePublished - Dec 2019


  • Adjuvants
  • Chagas
  • Immunity
  • Prophylactic
  • Therapeutic
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology


Dive into the research topics of 'Immunity and vaccine development efforts against Trypanosoma cruzi'. Together they form a unique fingerprint.

Cite this